Inhaled Steroid Growth Effect Should Not Discourage First-Line Use - Cmte.
Suppression of growth velocity in pediatric asthma patients should not discourage the first-line use of inhaled corticosteroids, FDA's Pulmonary & Allergy and Endocrine & Metabolism Drugs Advisory Committees determined July 31 at a joint meeting.
You may also be interested in...
Muro Pharmaceuticals is increasing production to launch its Tri-Nasal intranasal steroid medication by the start of the fall allergy season.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011